CompletedNCT03164876
Safety study of AUT00206 in schizophrenia
This study is completed in the United Kingdom. It is testing AUT00206 for schizophrenia.
In LondonSchizophreniaDrugA study involving a medication or substance.From 18 Years to 50 Years
Study directory
Back to overviewMental health studies with practical context.
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
CompletedNCT00743405
Safety study of GSK1034702 in Schizophrenia
This study is completed in the United Kingdom. It is testing GSK1034702 for Schizophrenia.
In LondonSchizophreniaDrugFrom 18 Years to 55 Years
CompletedNCT05447286
Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
This study is completed in the United States. It focuses on Addiction.
In New HavenAddictionDrugFrom 21 Years to 58 Years
CompletedNCT00908154
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
This study is completed in the United Kingdom. It focuses on Bipolarity.
In LondonBipolarity, DepressionDrugFrom 18 Years to 55 Years
CompletedNCT03327402
Safety study of SHP465 in ADHD
This study is completed in the United States. It is testing SHP465 for ADHD.
Multiple locations, including Little RockADHDDrugFrom 4 Years to 5 Years
WithdrawnNCT03546400
Safety study of Methylphenidate HCl ERCT in ADHD
This study was withdrawn. It is testing Methylphenidate HCl ERCT for ADHD.
Location not clearly listedADHDDrugFrom 48 Months to 69 Months
CompletedNCT01396447
Safety study of safety, Tolerability, and Efficacy of Cariprazine in Participants With Depression in depression in bipolarity
This study is completed in the United States, in Canada, in Bulgaria, .... It is testing safety, Tolerability, and Efficacy of Cariprazine in Participants With Depression for depression in bipolarity.
Multiple locations, including BirminghamBipolarity, DepressionDrugFrom 18 Years to 65 Years
CompletedNCT06816667
Safety study of Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT in depression
This study is completed in Argentina. It is testing Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for depression.
In San JuanDepression, AnxietyBehavioralFrom 40 Years to 80 Years
CompletedNCT01556763
Safety study of EVP-6124 in schizophrenia
This study is completed in the United States. It is testing EVP-6124 for schizophrenia.
In WichitaSchizophreniaDrugFrom 18 Years to 55 Years
CompletedNCT06253546
Safety study of TV-44749 in schizophrenia
This study is completed in China. It is testing TV-44749 for schizophrenia.
Multiple locations, including BeijingSchizophreniaDrugFrom 18 Years to 64 Years
SuspendedNCT02724917
Safety study of APN1125 in schizophrenia
This study is suspended in the United States. It is testing APN1125 for schizophrenia.
In Long BeachSchizophreniaDrugFrom 18 Years to 45 Years
CompletedNCT06005402
Safety, Tolerability, and Pharmacokinetics of CSX-1004
This study is completed in the United States. It focuses on Addiction.
In Overland ParkAddictionBiologicalFrom 18 Years to 50 Years
Public registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.